Breast Cancer | Specialty

HR+ Breast Cancer: FALCON

November 11th 2016

Ongoing Needs in HER2+ Breast Cancer

November 11th 2016

Neratinib in HER2+ Breast Cancer

November 11th 2016

Novel Strategies for HER2+ Metastatic Breast Cancer; Biosimilars

November 11th 2016

Treatment of HER2+ Metastatic Breast Cancer

November 11th 2016

Neoadjuvant T-DM1 in HER2+ Early Breast Cancer

November 11th 2016

Neoadjuvant Lapatinib in HER2+ Early Breast Cancer

November 11th 2016

Neoadjuvant Combinations in HER2+ Breast Cancer

November 11th 2016

HER2-Targeted Therapy in Early Breast Cancer

November 11th 2016

Palbociclib Approved in Europe for HR+/HER2- Breast Cancer

November 10th 2016

The European Commission approved palbociclib (Ibrance) for use in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting or combined with fulvestrant after progression on endocrine therapy.

Dr. Gabriel Hortobagyi on the Impact of MONALEESA-2 Trial in HR+ Breast Cancer

November 9th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses the MONALEESA-2 trial, which has shown that the addition of ribociclib to letrozole significantly improved progression-free survival (PFS) in postmenopausal women with hormone receptor (HR)­-positive advanced breast cancer.

Dr. Llombart-Cussac on Eribulin in HER2-Negative Metastatic Breast Cancer

November 8th 2016

Antonio Llombart-Cussac, MD, PhD, chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study, which assessed first-line eribulin (Halaven) for taxane-resistant patients with HER2-negative metastatic breast cancer.

Large Gene Network Required to Predict Response to HER2-Targeted Therapy

November 2nd 2016

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Palbociclib Demonstrates Consistent PFS Benefit in ER+ Breast Cancer

November 2nd 2016

Palbociclib demonstrated consistent improvement in progression-free survival when combined with endocrine therapy in patients with advanced estrogen receptor-positive breast cancer.

Dr. Blackwell on the Impact of the CLEOPATRA and MARIANNE Studies in HER2+ Breast Cancer

November 1st 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the lasting impact that the CLEOPATRA and MARIANNE studies have had on the treatment landscape in HER2-positive breast cancer.

FDA Grants Ribociclib Priority Review for Frontline HR+/HER2- Breast Cancer

November 1st 2016

The FDA granted a priority review to ribociclib for use in combination with letrozole as a frontline therapy for patients with hormone-receptor–positive, HER2-negative advanced breast cancer.

Dr. McGuire on Refinements Needed in Breast Cancer Surgery

October 28th 2016

Kandace McGuire, MD, associate professor of Surgery, UNC Department of Surgery, Division of Surgical Oncology, UNC School of Medicine, discusses refinements needed in surgery for the treatment of patients with metastatic breast cancer during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.

Experts Focus on New Ways of Attacking Resistance in ER+ Breast Cancer

October 26th 2016

Approximately 75% of invasive breast cancers are estrogen receptor (ER)–positive. Although ER-positive breast cancer typically responds well to initial endocrine therapy, most patients eventually become resistant to treatment and experience disease progression.

Dr. Hoftstatter on Impact of Molecular Testing on Genetic Abnormalities in Breast Cancer

October 26th 2016

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses what impact the advancements with molecular testing have had on the identification of genetic abnormalities in patients with breast cancer.

Breast Cancer's Complexity Pushes Researchers to Look Beyond the Genome

October 25th 2016

Although breast cancer research has helped chart the course for molecularly targeted therapies in oncology, next-generation sequencing technologies have revealed a disease so highly complex and heterogeneous that translating these findings into clinically useful therapies has proved daunting.